BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BC Innovations | Jan 23, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Cell culture and mouse studies suggest IL-29 and IL-28A could help prevent Zika infection in women. In primary human vaginal and cervical epithelial cells, pretreatment with IL-29 decreased Zika infection compared with...
BC Week In Review | Apr 14, 2014
Clinical News

PEG-IFN lambda: Phase IIb data

Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.   Product: PEG-IFN lambda (peginterferon lambda) ( PEG-rIL-29 )   Business: Infectious   Molecular target: Interleukin-29 (IL-29) (IFNL1)   Description: Pegylated recombinant IL-29   Indication: Treat HBV infection   Endpoint:...
BioCentury | Mar 24, 2014
Strategy

The price of success

Payers are so far covering the new HCV drugs from Gilead Sciences Inc. and Johnson & Johnson , but they are already looking forward to new drugs expected to hit the market in the next 18...
BC Innovations | Nov 7, 2013
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection IL-29 (IFNL1) Studies in patient samples suggest IL-29 could help treat the viral infections that frequently accompany atopic dermatitis. In skin biopsies,...
BC Week In Review | Nov 19, 2012
Clinical News

Daclatasvir: Phase IIb data

Interim data from 41 treatment-naïve patients with chronic HCV genotype 1 infection in the double-blind, international Phase IIb D-LITE trial showed that 90% (n=37) of patients achieved a protocol defined response (PDR) while receiving once-weekly...
BC Week In Review | Nov 19, 2012
Clinical News

PEG-IFN lambda: Interim Phase IIb data

Interim data from 41 treatment-naïve patients with chronic HCV genotype 1 infection in the double-blind, international Phase IIb D-LITE trial showed that 90% (n=37) of patients achieved a protocol defined response (PDR) while receiving once-weekly...
BC Week In Review | Nov 19, 2012
Clinical News

Asunaprevir: Phase IIb data

Interim data from 41 treatment-naïve patients with chronic HCV genotype 1 infection in the double-blind, international Phase IIb D-LITE trial showed that 90% (n=37) of patients achieved a protocol defined response (PDR) while receiving once-weekly...
BC Week In Review | Apr 23, 2012
Clinical News

PEG-IFN lambda: Additional Phase II data

Data from 118 treatment-naïve patients with chronic HCV genotype 2 or 3 infection in the Phase IIb portion of the international Phase II EMERGE trial showed that 65.5%, 75.9% and 60% of patients achieved an...
BC Extra | Apr 20, 2012
Clinical News

Bristol-Myers reports first SVR data for PEG-IFN lambda

Bristol-Myers Squibb Co. (NYSE:BMY) reported sustained virologic response data for 118 treatment-naive patients with chronic HCV genotype 2 or 3 infection treated with PEG-Interferon lambda in the Phase IIb portion of the Phase II EMERGE...
Items per page:
1 - 10 of 45